Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.53 |
| ▸ | PDCD1LG2 | Q9BQ51 | 11/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23198417 | 0.85 | CD274 (0.54) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL24722594 | 0.82 | CD274 (0.53) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL1776816 | 0.82 | CD274 (0.53) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21290762 | 0.73 | CD274 (0.40) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21322391 | 0.73 | CD274 (0.40) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21322394 | 0.73 | CD274 (0.40) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21290617 | 0.71 | CD274 (0.43) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21673405 | 0.71 | CD274 (0.43) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL14269728 | 0.71 | CD274 (0.43) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL18085891 | 0.71 | HDAC6 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1LG2 2/4885PDCD1 3/4885 |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1LG2 2/4885PDCD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.